Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
The Journal ofclinical investigation, 127(12), 42174227
Market Segmentation Global Glucagon-Like Peptide-1 Agonists Market Size, Share & Industry Analysis, By Product Type (Short-Acting GLP-1 Agonists, Long-Acting GLP-1 Agonists), By Route of Administration (Injectable, Oral), By Application (Type 2 Diabetes, Obesity Management, Cardiovascular Disease Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Analysis and Forecast 20262035 Global Glucagon-Like Peptide-1 Agonists Market Size & Statistics The Market size of global glucagon-like peptide-1 agonists was estimated to be worth USD 46.18 Billion in 2025
When should I call a doctor about nausea on GLP-1 therapy
Roche Johnson & Johnson Zealand Pharma Hanmi Pharmaceutical Rhythm Pharmaceuticals Structure Therapeutics Viking Therapeutics Altimmune Roche Diabetes Care Biocon Genfit Regeneron Pharmaceuticals Novo Nordisk Headquarters: Bagsvrd, Denmark Novo Nordisk is a global pharmaceutical company, kind of a leading player in diabetes and obesity care
In the United States, the Centers for Disease Control and Prevention (CDC) reports that over 38.4 million individuals, approximately 11.6% of the population, are currently living with diabetes [2]
%20(1).png)
